PharmaShots | Incisive News in 3 Shots

Subscribe Now

SLL

AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021

AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2...

June 14, 2021

Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL

Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL

March 5, 2019

AbbVie's Imbruvica (ibrutinib) + Gazyva (obinutuzumab) Receives FDA's Approval- First CT Free Treatment for 1L+ CLL/SLL

AbbVie's Imbruvica (ibrutinib) + Gazyva (obinutuzumab) Receives FDA's Approval- First CT Free Treatment for 1L+ CLL/SLL

January 28, 2019

Verastem Oncology's Copiktra (duvelisib) Receives FDA Approval for r/r 2L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Verastem Oncology's Copiktra (duvelisib) Receives FDA Approval for r/r 2L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma...

September 24, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us